Table I.

Overview of Reported Inhibitors of HAV with (Putative) Targets and Calculated Values for 50% Effective Concentrations (EC₅₀), 50% Cytotoxic Concentrations (CC₅₀), and Selectivity Indices (SI) When Provided

	Antiviral activity	Toxicity	SI	(Putative) target	Reference
IFNα‐2a	EC50: 90 IU/mL	CC50: >10,000 IU/mL	>100	Induction of antiviral state	112
Amantadine	EC50: 58 μM	CC50: 310 μM	5.3	HAV IRES‐mediated translation	117
Guanidine HCl	Variable inhibition between 0.1 and 3 mM	ND	ND	Protein 2C	99, 107, 119, 120, 121
Iota‐carrageenan	EC50: 2.5 μg/mL	CC50: >1000 μg/mL	>400	Attachment	122
Atropine	84% reduction in viral titer at 1.7 mM	CC50: >3.5 mM	ND	Attachment and/or uncoating	123
Glycyrrhizin	EC50: 325 μM	CC50: 5 mM	15	Membrane penetration	117
4,6′‐dichloroflavan	EC50: 6 nM	CC50: 45 μM	7500	Entry and/or uncoating	127
4,6′‐dichloroisoflavan	EC50: 6 nM	CC50: 90 μM	15,000	Entry and/or uncoating	127
Ribavirin	EC50: 94 μM	CC50: 430 μM	4.6	Inosine 5′‐monophosphate dehydrogenase	117
Pyrazofurin	EC50: 0.62 μM	CC50: 28 μM	45	Orotidine 5′‐monophosphate decarboxylase	117
Protamine	97% reduction in viral titer at 100 μg/mL	CC50: 200 μg/mL	ND	RNA polymerase	123
Ac‐LAAQ′‐fluoromethylketone	96% reduction in viral titer at 5 μM	ND	ND	Protein 3Cpro	143
Halopyridinyl ester	EC50: 53 nM	ND	ND	Protein 3Cpro	151

ND, not determined.

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.